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1. Introduction 
1.1 Patterns of lymphatic spread of Non-Small Cell Lung Cancer (NSCLC) 
The pattern and incidence of lymphatic spread of non-small cell lung cancer (NSCLC) is 
differentiated according to location, size and histologic type of primary tumors. As the 
primary tumor size increases, the incidence of lymphatic metastasis increases. Ogata et al 
reported the incidence of mediastinal lymphatic metastasis increased from 24% for tumors 
under 2 cm in size to more than 40% for tumors larger than 5 cm 1). Hata et al analyzed 192 
lymphoscintigraphies in 179 patients to determine the lymphatic drainage from each 
segmental bronchus into the mediastinum 2). For the right lobes, most of the lymph flowed 
into the right supraclavicular nodes through the subcarina or right paratracheal nodes. 
There were few drainages to the left supraclavicular nodes through subcarinal nodes. In 
contrast, the lymphatic drainage from the left lung was more variable, and four routes were 
determined, as follows. 
1. The route through the subaortic nodes. 
2. The route runs along the left phrenic nerve through the para-aortic nodes to the left 
supraclavicular nodes. 
3. The route runs along the left main bronchus to the left hilar or the left prevascular 
nodes. From the left hilar nodes, this route divides into two branches. One extends to 
the right supraclavicular nodes through the right upper paratracheal nodes. The other 
runs upwards along the left side paratracheal nodes 
4. The route runs under the left main bronchus to the subcarinal nodes. After passing the 
subcarinal nodes, this route extends to the right supraclavicular nodes along the trachea 
through the pretracheal nodes and the left upper paratracheal nodes. Some branches 
extend upwards along the left side of the trachea to the upper paratracheal and 
supraclavicular nodes. 
Fig. 1 shows the standard patterns of lymphatic drainage 2). These results suggest that most 
of mediastinal lymph node metastasis were found ipsilaterally in the right primary lung 
cancer, and the mediastinal or supraclavicular lymph node metastasis were found bilaterally 
in the left primary lung cancer. Nohl-Oser examined the location of nodal involvement in 
749 patients based on data obtained via mediastinoscopy, scalene lymph node biopsy and 
surgical specimen (Table 1) 3). The right upper lobe tumors spread to the right upper and  
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Fig. 1.A-G Standard patterns of lymphatic drainage. Each arrow shows the direction of the 
pathway of lymphatic drainage. The width of each the drain tubes indicates roughly the 
frequency of lymphatic drainage along each pathway. (From Hata E et al, References 2)  
 
Table 1. Pattern of mediastinal lymph node metastases (From Nohl-Oser HC, References 3) 
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lower paratracheal and supraclavicular nodes and rarely to subcarinal nodes or to the 
contralateral nodes. In contrast, right lower lobe tumors spread to the right hilar and 
subcarinal nodes. Left lobe tumors might cross the midline, and the right mediastinal nodes 
might be invaded. 
On the other hand, skip metastasis also occur more frequently in adenocarcinoma than in 
squamous cell carcinoma4). According to several authors, among cases without hilar node 
dissemination, routine mediastinal dissection revealed 6% unexpected mediastinal lymph 
node involvement (pN2), and an average of 34% of pN2 cases have mediastinal 
dissemination without hilar lymph node involvement 5). 
2. The evidence of IF-RT – Is ENI needed?  
In the standard radiation therapy for patients with unresectable advanced non-small-cell 
lung cancer (NSCLC), elective nodal irradiation (ENI) to the entire mediastinum, 
ipsilateral hilum and supraclavicular fossa has been deemed necessary due to anatomical 
lymphatic drainage and pathologic information regarding the high incidence of hilar and 
mediastinal node metastasis described Section 1. Recently, in order to improve the local 
control without increasing normal tissue toxicity, involved-field radiation therapy (IF-RT) 
using three or four dimensional conformal radiation therapy (3 or 4D-CRT) and intensity 
modulated radiation therapy (IMRT) technique for dose escalation is generally considered 
(Fig 2).  
In IF-RT for advanced NSCLC, whether ENI is necessary or not has been controversial. The 
argument against the use of ENI may be summarized as follows 6, 7). 1) Failure is uncommon 
in nodal regions that are neither clinically involved nor specially targeted from many 
reports 8-12). 2) It appears that a dose greater than the conventional 60-70Gy is required to 
cure a larger fraction of NSCLC patients. 3) The use of ENI causes severe adverse effects, 
such as radiation pneumonitis and esophagitis. 4) Clear progress has been made in staging 
by using FDG-PET. On the other hand, the argument against the omission of ENI may be 
summarized as follows 13-15). 1) The incidence of pathologically proven nodal metastasis 
even in stage I NSCLC may be as high as 26% 16), and the incidence of lymphatic invasion or 
metastasis rises with increasing tumor size 17). 2) Therefore many patients would die from 
distant metastasis or local failure, and ENF may not be often observed. 3) None of the 
studies on IF-RT provided pathologic confirmation of the status of nodal disease, nor data 
from autopsy findings. Thus, although there is a large discrepancy between IF-RT data and 
surgical data focused on ENF, actually many authors have reported retrospectively that 
ENF occurs in fewer than 10% of cases. In a phase I-II dose escalation study using IF-RT 
(RTOG 9311), the elective nodal failure rate was < 10% at last follow-up of 177 eligible 
patients 9). Senan et al reported 50 patients with unresectable stage IIIA or IIIB NSCLC were 
treated with sequential chemotherapy and IF-RT, and omitting elective mediastinal 
irradiation did not result in isolated nodal failure 11). Yu et al treated 80 patients 70 years or 
more with early stage (I / II) with IF-RT using intensity modulated radiation therapy 
(IMRT). Although 29 patients (36.7%) with ENF were identified, they concluded IF-RT using 
IMRT did not cause a significant amount of lymph node regions and improved outcomes in 
elderly patients 12). Matsuura et al reported 10 patients with locally advanced NSCLC (9 
patients in stage IIIB) were treated with hypofractionated IF-RT (median dose 65 Gy / 26 fr), 
and no ENF was encountered with good feasibility 18). 
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ENI (-): IF-RT                                                          ENI (+) 
Fig. 2.  
In the only prospective study comparing ENI with IF-RT, Yuan et al evaluated the effects of 
IF-RT in their prospective randomized trial in which 193 patients were randomly assigned 
to IF-RT to 68 to 74Gy or ENI to 60 to 64Gy using 3D-CRT, and reported that ENF was 
found in only 4% of patients in the ENI arm versus 7% in the IF-RT arm within 5 years 19). 
Although the irradiation dose to elective nodal regions was higher in the ENI arm than in 
IF-RT arm, ENF was not significant in either arm (p=0.351). They also demonstrated an 
increase in local control with IF-RT of 8%, 8% and 15% at 1, 2 and 5 years, respectively. 
Fernandes et al reported a comparative analysis of ENI vs IF-RT. They concluded nodal 
failure rates in clinically uninvolved nodal stations were not increased with IF-RT when 
compared to ENI, and also resulted in significantly decreased esophageal toxicity, 
suggesting that IF-RT may allow for integration of concurrent systemic chemotherapy in 
greater proportion of patients with NSCLC 20). Although we don’t have the conclusions 
whether ENI is necessary or not, recent clinical trials of NSCLC have adopted IF-RT and IF-
RT is going to be mainstream of radiation therapy for NSCLC.  
3. Incidental irradiation of IF-RT 
An interesting question is why the incidence of ENF is so low. It may be that incidental 
irradiation to clinically uninvolved nodal regions may help to explain the low incidence of 
ENF. Chen et al reported the results of IF-RT using 3D-CRT technique and examined 
incidental irradiation and ENF in thirty-five patients with inoperable early-stage NSCLC 
(T1-3N0M0) 21). Although the incidental irradiation to regional nodal stations was low 
(fewer than 10% of all nodal regions received a dose of >40Gy), ENF was observed in only 
two patients who developed nodal relapse after local progression, and no patients failed 
initially at nodal sites. They concluded that the incidence of nodal failure was low and did 
not seem to be due to high-dose incidental irradiation. Rosenzweig et al reported the results 
of IF-RT in a large number (524) of patients with stage I-III (65% stage III) NSCLC 8). Only 32 
patients (6.2%), 42 nodal regions with ENF were identified, and among the 42 nodal regions, 
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six regional failures (14%) were in nodal regions that had incidentally received >45Gy, 
which is a typical dose of ENI. Jeremic analyzing these data of Rosenzweig et al noted that 
only 14% of nodal failures occurred in regions receiving >45Gy, whereas nodal failures 
happened in 86% of patients when nodal regions received less than 45Gy (p<0.01) 13). Chapet 
et al reported the results of IF-RT in 40 patients with stage III NSCLC, and analyzed 
incidental irradiation to non-involved nodal stations 22). The doses of incidental irradiation 
at level 4R, 4L, 7 and 10I were relatively high. They concluded that significant incidental 
irradiation was observed, with this possibly helping to explain the low rate of regional 
recurrence observed when ENI is not applied with stage III NSCLC treated with 3D-CRT 
technique. Kimura et al also evaluated the incidental irradiation dose to elective nodal 
regions in 50 patients with locally advanced NSCLC who treated IF-RT and the pattern of 
ENF 23). ENF was observed in 4 patients (8%) five nodal regions, and no mean dose to the 
nodal region exceeded 40 Gy. Although these reports were retrospective in nature, as the 
stage of NSCLC advanced, especially to stage III, we have the impression that high-dose 
incidental irradiation may contribute to the low incidence of ENF in the patients receiving 
IF-RT. 
4. Treatment planning of IF-RT – Especially, impact of FDG-PET on radiation 
therapy volume delineation 
Although there are some points about the practical treatment planning of IF-RT, the most 
important point is the judgment of metastatic lymph nodes on CT or FDG-PET. Therefore 
evidence already exists that PET-based patient selection can improve the apparent survival 
of patients treated with RT for NSCLC 24), and the routine omission of ENI without 
considering the accuracy of staging by using FDG-PET may not be advisable. Thus, FDG-
PET should be recommended as a useful tool in enhancing staging accuracy and RT 
planning 25). The use of FDG-PET also may contribute to the low incidence of ENF in IF-RT.  
On the other hand, the SUV (standardized uptake value) cutoff value chosen have been 
controversial. Using SUV > 2.5 or regions of 40% maximum SUV, a lesion is usually 
considered malignant unless proved otherwise 24). However, exclude use of SUV can be 
misleading 25). We recommend to diagnose the positive lymph nodes by the following points 
consulting with the nuclear medicine physician 27). 1) An increased uptake to a level greater 
than that in the mediastinal blood pool activity was considered to characterize malignancy. 
2) FDG-PET image was performed at 1-hour (early) post-FDG injection and repeated 2-
hours (delayed) after injection only in the thoracic area. Using dual-time point FDG-PET 
(combined early and delayed PET), we calculated the retention index (RI): (SUV delayed –
SUV early)×100/ SUV early. RI values of more than 0% were taken to be the PET criterion 
for malignancy. Fig 3 shows an example. 
Although there is no doubt the use of FDG-PET is effective on radiation treatment planning, 
we should pay attention on some pitfalls. Vanneste et al described one should be cautious to 
repeat the diagnostic FDG-PET scan for each patient if the time-interval between the staging 
FDG-PET-CT scan and the start of the irradiation is 4 weeks or more 28). Additionally, we 
should reconsider CT diagnosis of metastatic lymph nodes define more than 1cm in the 
short axis, especially in regions where enlarged lymph nodes are rarely seen (para-aortic, 
retrocrural or pericardial fat). 
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Fig. 3. The right primary lung cancer (squamous cell carcinoma) in a 79-years-old man. a) 
The early F-18- uorodeoxyglucose positron emission tomography (FDG-PET) image (coronal 
view) demonstrates focal accumulation in the right upper lobe and right tracheobronchial 
node (arrowhead). b) The delayed FDG-PET image (coronal view) shows intense FDG 
uptake at right tracheobronchial node (arrowhead). c) Another early FDG-PET image 
(coronal view) shows abnormal uptake at right peribronchial node (small arrow), subcarinal 
node (large arrow), and aortopulmonary node (arrow- head). Standardized uptake value for 
early images (SUVearly) was 5.86 at right tracheobronchial node, 3.37 at right peribronchial 
node, 3.92 at subcarinal node, and 3.41 at aortopulmonary node. d) Another delayed FDG-
PET image (coronal view) shows slight uptake at right peribronchial node (small arrow) and 
aortopulmonary node (arrowhead) and mild uptake at subcarinal node (large arrow). 
Standardized uptake value for delayed images (SUVdelayed) was 7.36 at right 
tracheobronchial node and retention index (RI) was 25.6. SUVdelayed was 2.71 and RI -19.6 
at right peribronchial node, SUVdelayed 3.56 and RI -9.2 at subcarinal node, and 
SUVdelayed 3.27 and RI -4.1 at aortopulmonary node. Nodal staging based on early and 
delayed FDG-PET demonstrated N3 stage. However, nodal staging based on combined 
delayed PET with RI value, demonstrated N2 stage. The surgical result also indicated N2 
stage. (From Nishiyama Y et al, References 27) 
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5. Conclusions 
However whether ENI is necessary or not has been still controversial for advanced NSCLC, “If 
one can’t control gross disease, why enlarge the irradiated volumes to include areas that might 
harbor microscopic disease? 29)” IF-RT is deemed an acceptable method for advanced NSCLC 
without increasing the risk of ENF or adverse effects, but further clinical trials are needed. 
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